Technetium (99mTc) tilmanocept, sold under the brand name Lymphoseek, is a radiopharmaceutical diagnostic imaging agent used to locate lymph nodes which may be draining from tumors, and assist doctors in locating lymph nodes for removal during surgery.[6]
The most common side effects include pain or irritation at the injection site.[7]
It was approved for medical use in the United States in March 2013,[4][7] and in the European Union in November 2014.[5]
In the US, technetium (99mTc) tilmanocept is indicated with or without scintigraphic imaging for lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in people with solid tumors for which this procedure is a component of intraoperative management; and guiding sentinel lymph node biopsy using a handheld gamma counter in people with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma.[4][7]
In the EU, technetium (99mTc) tilmanocept is indicated for imaging and intraoperative detection of sentinel lymph nodes draining a primary tumor in adults with breast cancer, melanoma, or localized squamous cell carcinoma of the oral cavity.[5] External imaging and intraoperative evaluation may be performed using a gamma detection device.[5]
The safety and effectiveness of technetium (99mTc) tilmanocept were established in two clinical trials of 332 participants with melanoma or breast cancer.[7] All participants were injected with technetium (99mTc) tilmanocept and blue dye, another drug used to help locate lymph nodes.[7]
This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
This medical diagnostic article is a stub. You can help Wikipedia by expanding it.
Lokasi Pengunjung: 18.117.159.167